A study on pharmacokinetics of bosentan with systems modeling, Part 1: translating systemic plasma concentration to liver exposure in healthy subjects

Rui Li, Mark Niosi, Nathaniel Johnson, David A. Tess, Emi Kimoto, Jian Lin, Xin Yang, Keith A. Riccardi, Sangwoo Ryu, Ayman F. El-Kattan, Tristan S. Maurer, Larry M. Tremaine, and Li Di

Translating bosentan systemic exposure to liver exposure

Corresponding Author

Rui Li. Systems Modeling and Simulation, Medicine Design, Pfizer Worldwide R&D, Cambridge, MA. Phone: 617-551-3340. Email: Rui.Li5@pfizer.com

Number of text pages: 12
Number of tables: 4
Number of Figures: 7
Number of references: 34
Number of words in Abstract: 178
Number of words in Introduction: 627
Number of words in Discussion: 1331
Abbreviations

BSEP: bile salt export pump
CYP: cytochrome P450
DDI: drug-drug interaction
DILI: drug-induced liver injury
ECCS: Extended Clearance Classification System
ET: endothelin receptors,
$K_{puu}$: unbound tissue-to-unbound systemic plasma concentration ratio
$K_{pu}$: total tissue-to-unbound systemic plasma concentration ratio
MCMC: Markov chain Monte Carlo
MRP: multidrug resistance-associated protein
NTCP: sodium-taurocholate co-transporting polypeptide
OATP: organic anion transporting polypeptide
PBPK: physiologically based pharmacokinetic
PD: pharmacodynamics
PET: positron emission tomography
PK: pharmacokinetics
PXR: pregnane X receptor
RBC: red blood cells
SCHH: sandwich cultured human hepatocyte
TMDD: target mediated drug disposition
UGT: UDP-glucuronosyltransferase
Abstract

Understanding liver exposure of hepatic transporter substrates in clinical studies is often critical as it typically governs pharmacodynamics, drug-drug interactions, and toxicity for certain drugs. However, this is a challenging task since there is currently no easy method to directly measure drug concentration in the human liver. Using bosentan as an example, a new approach has been demonstrated to estimate liver exposure based on observed systemic pharmacokinetics from clinical studies using physiologically-based pharmacokinetic modeling. The prediction has been verified to be both accurate and precise using sensitivity analysis. For bosentan, the predicted pseudo steady state unbound liver-to-unbound systemic plasma concentration ratio ($K_{puu}$) is 34.9 with a 95% confidence interval of 4.2 to 50. Drug-drug interaction (i.e., cytochrome P450 (CYP) 3A and 2B6 induction) and inhibition of hepatic transporter (i.e., bile salt export pump (BSEP), multidrug resistance-associated proteins (MRPs), and sodium-taurocholate co-transporting polypeptide (NTCP)) are predicted based on the estimated unbound liver tissue or plasma concentrations. With further validation and refinement, it is concluded that the approach may serve to predict human liver exposure and complement other methods involving tissue biopsy and imaging.
**Introduction**

The pharmacokinetics (PK) of many drugs can be influenced by transporters. Since transporter-mediated disposition (e.g., organic anion transporting polypeptides, OATPs) can be independent of substrate concentration gradient, drugs may accumulate or be excluded from tissues. Therefore, even without considering factors like membrane potential, it may not be accurate to assume that unbound tissue concentration is equivalent to unbound plasma concentration \(K_{puu} = 1\). Since both transporters and metabolism affect drug concentration in the liver, there are two challenges for drug discovery: (1) predicting systemic exposure, which is dependent upon the interplay between transporters and metabolism in the liver, and (2) predicting liver exposure, which may drive pharmacodynamics (PD), toxicity, and drug-drug interaction (DDI). In the drug development phase, even with clinical data, predicting liver exposure may still be ambiguous in relating observed plasma PK to tissue-exposure-driven clinical outcomes.

To address the challenge of understanding human liver exposure, positron emission tomography (PET) studies for transporter substrates have been developed (Shimizu et al., 2012; Gormsen et al., 2016). In addition to excessive cost and potential difficulties in labeling compounds, the usefulness of this approach is still limited to compounds with minimal metabolism. For the majority of drugs with significant metabolism, the PET data is confounded by metabolite signals. As such, in the foreseeable future, translating observed systemic concentration to liver concentration with mechanistic modeling (e.g., physiologically based pharmacokinetic, PBPK models) may be one of the most effective tools to enable a greater understanding of human liver exposure. However, this approach has its limitations, including non-ideal systemic data making the PBPK model unidentifiable, so that many sets of parameter values can equally describe the systemic plasma data, but lead to different liver exposure predictions (Li et al., 2016).

From such a perspective, bosentan is a great example as its systemic exposure data can provide enough information for PBPK modeling to confidently predict liver concentrations. Bosentan is a dual endothelin receptor antagonist, used to treat pulmonary arterial hypertension (Dingemanse and van Giersbergen, 2004). Being an Extended Clearance Classification System (ECCS) 1B compound (El-Kattan et al., 2016), in human bosentan...
is transported into the liver by uptake transporters including OATP1B1 and OATP1B3 (Treiber et al., 2007) and then metabolized by cytochromes P450 (CYP) 3A and 2C9 (Dingemanse and van Giersbergen, 2004), with minimal unchanged drug recovered in urine and feces following intravenous dosing (Weber et al., 1999b). Although the PK profile of bosentan is more complicated than other compounds (e.g., nonlinear disposition and distribution (Weber et al., 1996)), these can be addressed with a carefully calibrated model. Bosentan is not characterized by significant biliary excretion or enterohepatic recirculation, which would have made data interpolation very challenging.

Understanding bosentan liver exposure is also important for predicting CYP induction and inhibition. Several groups have reported that bosentan is an inducer for CYPs (van Giersbergen et al., 2002a; Dingemanse and van Giersbergen, 2004; Fahmi et al., 2008; Srinivas, 2016; Sun et al., 2017). Results of in vitro studies also show that bosentan inhibits the bile salt export pump (BSEP), multidrug resistance-associated protein (MRP) 3 and 4 (Morgan et al., 2013), sodium-taurocholate co-transporting polypeptide (NTCP) (Leslie et al., 2007), which may result in drug-induced liver injury (DILI) (Leslie et al., 2007; Morgan et al., 2013). Hepatic CYP induction and transporter inhibition is likely driven by liver concentration, so a highly confident prediction of liver concentration is critical to understand clinically observed DDI and DILI.

In this study, we have developed a PBPK model for bosentan incorporating its various PK properties, and generated liver exposure and its confidence intervals using a Markov chain Monte Carlo (MCMC) approach. The key parameters are determined either in preclinical assays or by simultaneously fitting data from eight independent clinical studies (Table 1) to avoid potential model misspecifications due to improper assumptions.

Materials and Methods

A mechanistic model to analyze pharmacokinetic data

Framework. A new PBPK model (with scheme in Figure 1) is developed based on a published structure (Li et al., 2014). Table 2 provides all the parameters with fixed values, except for the physiological parameters listed in Supplemental Materials (Supplemental
Systemic circulation and non-liver tissue distribution. The arterial blood, venous blood, and lung are lumped as systemic blood, which is then split into systemic plasma and red blood cells (RBC). Due to potential nonlinear binding kinetics, instead of assuming constant plasma unbound fraction ($f_{u,p}$) or blood to plasma ratio ($R_{B/P}$), we use the kinetic model to describe binding in plasma and RBC. For example, binding in the plasma is modeled with mass balances of unbound concentration, bound concentration, and available binding site concentration (Equation 1 to 3)

$$\frac{dC_{unbound}}{dt} = -k_{on} \cdot C_{unbound} \cdot C_{available-site} + k_{off} \cdot C_{bound}$$ (1)

$$\frac{dC_{available-site}}{dt} = -k_{on} \cdot C_{unbound} \cdot C_{available-site} + k_{off} \cdot C_{bound}$$ (2)

$$\frac{dC_{bound}}{dt} = k_{on} \cdot C_{unbound} \cdot C_{available-site} - k_{off} \cdot C_{bound}$$ (3)

The binding in RBC is modeled similarly; passive permeation ($CL_{systemic,blood,pass}$) is assumed between RBC and plasma. All components in the systemic blood are connected with their counterparts in the liver and small intestine villi blood.

$k_{on}$ rates for all binding processes in this study are fixed at $10^9$ mol$^{-1}$·sec$^{-1}$ (3600 nmol$^{-1}$·hour$^{-1}$) assuming the diffusion limited reaction (Alberty and Hammes, 1958). $k_{off}$ and the total concentrations of binding site in plasma and RBC are estimated by fitting in vitro unbound fraction and blood to plasma ratio at various concentrations (Supplemental Materials Figure S1) with a mechanistic model. As the model is not sensitive to $CL_{systemic,blood,pass}$, this parameter is fixed at the product of total systemic RBC surface area and a permeability approximated using hepatocytes; details provided in Supplemental Materials.

For non-liver tissues, instantaneous equilibrium between tissue and unbound systemic plasma is assumed, defined by in silico predicted $Kp_u$ (i.e., total tissue to unbound plasma
The target mediated drug disposition (TMDD) has been proposed in previous studies (Mager and Jusko, 2001; Volz et al., 2017), but it’s unlikely that the targets (i.e., endothelin receptors, ET) or their internalization will eliminate the compound. As such, TMDD is modeled as a specific binding process to the ET in the plasma compartment, with parameters optimized by fitting clinical data.

The liver. The model includes five sequential liver segments, each containing three components: plasma, RBC, and tissue. Each component is further divided into three sub-components to represent unbound, bound compound, and available binding site. There are hepatic active uptake, active basal efflux, and passive diffusion between plasma and tissue, plus metabolism within the tissue. The biliary excretion is assumed to be minimal for bosentan based on the fact that: (1) in vitro sandwich cultured human hepatocyte (SCHH) showed no biliary excretion (data provided in Part 2 of this study, which is published in a separated article), and (2) minimal compound is excreted into feces following intravenous dosing in humans (Weber et al., 1999b). With the exception of passive diffusion clearance \( CL_{\text{liver,pass}} \), hepatic processes are assumed to follow Michaelis-Menten kinetics. Among Michaelis-Menten constants, \( KM_{\text{liver,uptake}} \) and \( KM_{\text{liver,metabolism}} \) are fixed at values based on in vitro assays. Due to low confidence in the in vitro values, \( KM_{\text{liver,efflux}} \) is estimated by fitting clinical data, together with \( k_{\text{liver,uptake}}, k_{\text{liver,efflux}}, k_{\text{liver,metabolism}} \) and \( CL_{\text{liver,pass}} \). Blood binding parameters share the same values as those in circulating blood. Intracellular binding parameters are fixed at values estimated from in vitro hepatocyte assays in Part 2.

Absorption parameters. The oral absorption is modeled using a semi-mechanistic model with a first order rate constant \( k_a \) and fraction absorbed \( F_a \). An enterocyte compartment is created between dissolved drug compartment and small intestine villi blood. Passive diffusion \( CL_{\text{enterocyte,pass}} \) and active efflux \( CL_{\text{enterocyte,efflux}} \) are assumed between enterocytes and small intestine villi blood, and metabolism in the enterocytes. Binding in villi blood is modeled the same as that within systemic and liver blood. Fraction absorbed \( F_a \) is determined using clinical \( ^{14}\)C data (with details provided in Supplemental Materials). Two different \( k_a \) values under fasted and fed conditions, \( CL_{\text{enterocyte,pass}}, CL_{\text{enterocyte,efflux}} \) and
enterocyte intracellular free fraction \((f_{\text{u, enterocyte}})\) are estimated by fitting clinical data. Although apparent \(K_M\) values for enterocyte and liver metabolism may be different due to potentially different CYPs involved in the tissues, we assume that \(K_{M, \text{enterocyte, metabolism}}\) shares the same value with \(K_{M, \text{liver, metabolism}}\) based upon fact that the in vitro CYP3A- and 2C9 have similar \(K_M\) values (Shen et al., 2009), whereas the metabolic rate is scaled from \(k_{\text{liver, metabolism}}\) based on CYP abundances in the human liver and gut (details provided in Supplemental Materials).

**Induction parameters.** In vivo CYP induction is described using a turnover model. Because bosentan induces CYPs via pregnane X receptor (PXR) agonism (van Giersbergen et al., 2002a), we assume that different CYPs involved in hepatic and intestinal metabolism share the same induction \(E_{\text{max}}\) and \(EC_{50}\) values, which is supported by the similar values identified from the in vitro CYP3A4 and 2B6 activity assay described below. \(E_{\text{max}}\) is estimated by fitting clinical data of bosentan and victim drugs (see below), while \(EC_{50}\) is fixed at an average value from the in vitro assay (i.e., 1000 nM). CYP degradation rate \((k_{\text{degradation}})\) is calculated as \(\ln(2)\) divided by half-life. Because there is no published clinical data regarding CYP2C9 half-life, it is assumed that degradation rate \((k_{\text{liver, degradation}})\) of CYP2C9 equals that of CYP3A4, estimated from a clinical CYP3A4 inactivation study (27.7 hours (Quinney et al., 2010)). The enterocyte half-life (23.1 hours (Yang et al., 2008)) is applied to enterocyte CYPs, assuming half-life values of CYPs are determined by the shorter half-life of enterocyte.

**BSEP, MRP, NTCP inhibition.** Competitive inhibition of four transporters was calculated independently based on simulated bosentan unbound plasma (for NTCP) or intracellular (for BSEP and MRP) concentrations and in vitro \(IC_{50}\) values (Leslie et al., 2007; Morgan et al., 2013). Maximal inhibition is assumed to be 100%. There is no supporting evidence that inhibition affects bosentan exposure.
**Victim drugs.** A reduced PBPK model is developed for victim drugs (i.e., tadalafil and warfarin) co-dosed with bosentan (Supplemental Materials). Published bosentan induction DDI studies with other drugs are not included in the modeling since it is challenging to simulate victim liver exposure (e.g., transporter substrates: simvastatin and glyburide) or because victim drugs also affect bosentan exposure (e.g., glyburide reduces bosentan exposure, and sildenafil increases bosentan exposure). For victim drugs, bosentan may change its gut metabolism ($F_g$), hence we assume that their $F_g$ values are different with and without bosentan. Since it is difficult to separate $F_a$ from fraction escaped from $F_g$, $F_aF_g$ is modeled as a single parameter. It is fixed at one in the absence of bosentan, but fitted against clinical data in the presence of bosentan. Parameters for victim drugs in the absence of bosentan are listed in Supplemental Table S2.

Parameter optimization and prediction of liver exposure

Bosentan data from eight clinical studies are included for parameter optimization (Table 1). The model is implemented in MATLAB 2016a (MathWorks, Natick, MA, US). Parameter estimation is performed with differential evolution, while the uncertainty is quantified using MCMC (Markov chain Monte Carlo). MCMC provides ranges of parameter values that are able to reasonably describe the data. We randomly sampled 1000 sets of parameter values from all values ($8 \times 10^5$ sets) identified in MCMC that adequately describe systemic plasma data. 1000 simulations using sampled parameter values were generated, such that uncertainty in parameter estimation was reflected in the simulations.

In vitro induction assay and modeling

An in vitro hepatocyte induction study was performed to understand if the CYP induction could be accurately predicted using primary hepatocytes. The data are analyzed using a mechanistic model which combines SCHH model and CYP turnover model mentioned above. Details are provided in the Supplemental Materials.

Results
Fitting clinical systemic data and estimating parameters

With optimized parameter values, the model can reasonably describe the mean systemic exposures of both bosentan and victim drugs following intravenous or oral administration with various doses (Figure 2, 3, and 4) obtained from several studies. Parameters can be confidently estimated (Table 3) with the exception of $CL_{\text{enterocyte, pass}}$, $CL_{\text{enterocyte, efflux}}$, $k_{\text{liver, efflux}}$, and $K_{M, \text{liver, efflux}}$. This is potentially due to correlation among the different parameters, or insensitivity of simulations to these parameters.

Simulating liver exposure

Despite the fact that some parameters cannot be confidently identified by fitting systemic data, the predicted liver exposure is still reasonably precise (Figure 5). The predicted pseudo steady state ratio between unbound liver tissue and unbound systemic plasma concentrations ($K_{puu,\text{liver}}$, i.e., the ratio during the elimination phase of systemic PK) following 125 mg bosentan BID dosing is 34.9 with 95% confidence interval (CI) of 4.2 and 50. The time course of unbound liver tissue to unbound systemic plasma following 62.5, 125, or 500 mg BID dosing are provided in Figure 5 (B, E, and H), where the median values change between 20 and 40. Please note that $K_{puu,\text{liver}}$ calculated here is the ratio of unbound liver tissue to unbound systemic plasma concentration, but not to unbound liver plasma concentration. Hypothetically, there is a difference in concentration between systemic plasma and liver plasma due to liver extraction.

CYP induction

With the data included in this study, a liver induction effect of around 1.5-fold and a gut induction effect of about 2-fold are estimated, depending on the dosing amounts (Figure 5C, F, and I). The result is consistent with a previous clinical study where bosentan increases the urinary excretion of 6β-hydroxycortisol (an endogenous marker of CYP3A4 activity) 1.7-fold (Weber et al., 1999c). Following 125 mg twice daily oral dosing for ten days, using metabolic rate estimated in MCMC, bosentan $F_g$ is calculated to be 0.630 (95% CI: 0.57, 0.68) during the first dose, and 0.473 (95% CI: 0.41, 0.53) during the last dose.
The ratio between two $F_g$ is 0.751 (95% CI: 0.70, 0.81). Overall, the model attributes more induction effect to gut rather than liver, which is similar to a previous results published for DDI between repaglinide and rifampin (Varma et al., 2013). Since tadalafil absolute bioavailability is unknown, and we arbitrarily assume its $F_aF_g$ to be 1 in the absence of bosentan, the estimated $F_aF_g$ in the presence of bosentan (Table 3) is essentially the ratio of $F_aF_g$ between two conditions. Further assuming its $F_a$ is not affected by bosentan, its $F_g$ in the presence of bosentan is reduced to 0.868 (95% CI: 0.70, 1.0) of $F_g$ value in the absence of bosentan. This is consistent with bosentan $F_g$ changes described above. For warfarin, this ratio is around 1 (Table 3). This is consistent with the fact that warfarin bioavailability (and hence $F_g$) is nearly 1 (Holford, 1986) (i.e., warfarin has minimal gut metabolism).

We have also generated in vitro CYP3A and 2B6 induction data using human hepatocytes (Table 4, Supplemental Figure S2) to understand the prediction accuracy of the current in vitro tool. By measuring activity, prediction from lot HH1025 is closest to the in vivo simulations, while the other two lots (i.e. HC7-4 and FOS) would over-predict in vivo induction (Figure 6). By measuring mRNA, the assay over-predicts observed induction based on clinical data, which is consistent with another CYP inducer, rifampin (in-house data not shown).

**BSEP, MRP, NTCP inhibition**

With the predicted unbound liver tissue or plasma exposure and published $IC_{50}$ values estimated from in vitro data, the model predicts moderate inhibition (up to 18%) for these transporters (Figure 7).

**Discussion**

This study aims to predict the liver concentration of a transporter substrate by leveraging a PBPK model that utilizes available clinical (systemic plasma concentration) data. The underlying mechanism for such a prediction is the conservation of mass: the total amount of the compound in systemic blood, liver, non-liver tissues, and the compound metabolized
is equal to the dosed amount. In such a scenario, the dosed amount is known. The amount in systemic blood is based on measured plasma concentrations, amount in non-liver tissue is predicted with in silico methods, and the amount metabolized can be calculated using hepatic metabolic rate estimated from systemic data. As a result, the amount in the liver can be deduced. A precise and accurate “deduction” is based upon three criteria. First, the model’s ability to accurately describe systemic data (amount in systemic blood) is a prerequisite for predicting liver concentration, which explains why we establish this relatively complex PBPK model incorporating multiple nonlinear processes. Second, there must be sufficient data to enable confident estimation of hepatic metabolism. For certain compounds, their clinical data cannot satisfy this requirement as described previously (Li et al., 2016). With a MCMC approach, we have shown that bosentan metabolism can be precisely estimated from its clinical systemic data. Third, an accurate description of distribution into non-liver tissues is critical, which is usually predicted by the in silico estimated $K_{pu}$ values in human PBPK modeling. To understand how inaccurate non-liver $K_{pu}$ (distribution into non-liver tissues) may affect liver $K_{puu}$ estimation, we have applied a scaler for non-liver $K_{pu}$ at the value of 0.1 or 10, and re-estimated liver $K_{puu}$. With a non-liver $K_{pu}$ scaler of 0.1, the goodness of fitting of the systemic data is about the same as that without using a scaler, and liver $K_{puu}$ is about 40. The latter is still within the confidence interval of liver $K_{puu}$ without non-liver $K_{pu}$ scaler. On the other hand, with a non-liver $K_{pu}$ scaler of 10, the goodness of fitting is significantly worse (i.e. objective function value increased by 5 fold), and the liver $K_{puu}$ cannot be confidently identified. We have also tried to estimate a $K_{pu}$ scaler by including it as another fitted parameter; however, this parameter cannot be precisely estimated. In a monkey study presented in Part 2 of this work, where both systemic and liver exposure are determined experimentally, we can confidently estimate the non-liver $K_{pu}$ scaler as 1.47, which justifies a value of 1 in the present exercise.

Binding to bosentan’s pharmacology target may also affect distribution. The ratio, $K_D$, between ET $k_{off}$ and $k_{on}$ is estimated to be 4.30 (with 95% CI between 1.4 and 11), which is very close to experimentally determined values (Russell and Davenport, 1995; Bacon and Davenport, 1996; Gatfield et al., 2012). Although we set these parameters for ET binding, the optimization process may also use them to describe tissue distribution not explained by tissue $K_{pu}$ fixed at the in silico predicted values. The fact that the estimated
KD value is similar to experimentally determined values suggests non-liver Kpu used in the model is likely accurate. Alternatively, if non-liver Kpu was inaccurate, the model would likely incorrectly estimate ET KD.

Bosentan is mostly metabolized by CYP3A with a minor contribution from CYP2C9 (70% versus 10%, supplemental materials). For the induction victim drugs, tadalafil is primarily metabolized by CYP3A (Wrishko et al., 2008), CYP3A contributes to (R)-warfarin clearance, and (S)-warfarin is largely metabolized by CYP2C9 (Weber et al., 1999a). To reduce the number of fitted parameters, we assume that different CYPs share the same induction Emax and EC50, based on the fact that bosentan induces CYP via PXR-mediated mechanisms. It is difficult to validate this assumption without additional clinical data. Because the estimated hepatic induction effect is minimal, the specific values for each hepatic CYP are unlikely to significantly affect current simulations. For enterocyte induction in the gut, which is stronger than hepatic induction, we assume that induction is compound-specific. Nonetheless, we have also re-estimated liver Kpu after removing data from victim drugs. Neither estimated parameter values nor Kpu changes significantly. As a result, even if the future data show that assumption made here for hepatic induction Emax and EC50 is incorrect, it should not significantly confound the liver simulations. It is worth noting that simulated induction effect (Figure 5C, F, and I) is consistent with the result of a previous clinical study where an endogenous marker of CYP3A4 activity was monitored. In addition, estimated changes of Fg values due to induction are similar between bosentan and tadalafil. These results are consistent with the fact that bosentan and tadalafil are mostly metabolized by CYP3A.

An average of 10% transporter inhibition is predicted, but the PBPK model does not include bosentan metabolites, which may lead to more inhibition. However, it is out of scope of the current study to determine how much inhibition is required to cause DILI.

To increase confidence in the simulations, the model is trained with data collected from several clinical studies. Although intravenous bolus studies are generally excluded from first-in-human studies due to the cost of developing formulation, safety concerns, etc. It may, however, be a cost effective way to understand liver exposure (i.e., exposure at the site of action) compared to other approaches, such as PET, which can be difficult to
interpret due to metabolite interference. We therefore recommend human intravenous bolus studies collecting data in both distribution and terminal phases for future clinical trials to provide a greater understanding of liver exposure for compounds undergoing metabolism. With only oral data, there are additional fitted absorption parameters which may lead to over-parameterization. Oral studies may be acceptable for compounds with known $F_aF_g$. Failure in collecting data in terminal phase may add uncertainty in identifying hepatic metabolism and liver exposure. If parameters cannot be confidently estimated even with intravenous data, the Bayesian based approaches may have to be used with the risk of using inaccurate priors. For compounds with minimal metabolism but extensive biliary excretion and enterohepatic recirculation, PBPK modeling is restricted by our limited understanding of elimination mechanisms, whereas PET studies may provide more straightforward results. For compounds with both metabolism and enterohepatic recirculation (e.g., UDP-glucuronosyltransferase, UGT substrates), we cannot see any clinical approach beneficial in understanding their liver exposures so far.

Yoshikado et al. reported that a generally accepted CYP3A inhibitor, itraconazole, did not significantly change bosentan systemic exposure in human (Yoshikado et al., 2017). The authors estimated in vivo CYP3A inhibition by itraconazole using orally administered midazolam as a victim compound (where plasma AUC ratio was 3.7), and assumed that itraconazole could inhibit bosentan metabolism to the same level. The fact that itraconazole did not change bosentan systemic exposure led the authors to conclude that the ratio of hepatic metabolism to passive diffusion was high, such that the change of metabolism within the liver was not reflected in systemic exposure. This conclusion contradicts our parameter estimation, where passive diffusion is high enough so CYP3A inhibition will change systemic exposure (simulation not shown). It worth noting that in the Yoshikado study, itraconazole did not significantly change bosentan metabolite exposure either. It is possible that itraconazole cannot sufficiently inhibit bosentan metabolism under in vivo conditions, hence it would not affect bosentan systemic exposure, independent of bosentan’s permeability. In addition, a second CYP3A inhibitor, ketoconazole, has been shown to significantly alter bosentan systemic exposure (van Giersbergen et al., 2002b), which is consistent with our prediction.
In conclusion, using bosentan data, we have provided an example to demonstrate how to translate the systemic concentration of a hepatic transporter substrate into its liver exposure by leveraging a PBPK based “deduction” method. The precision and accuracy of such a translation has been evaluated and discussed also. As described, the new approach supports determination of drug liver exposure in humans based on existing clinical data, as information regarding the exposure at the site of action is critical for hepatic transporter substrates when attempting to understand their PD, DDI, toxicity in the liver, and therapeutic index.
Acknowledgments

We thank Drs. David Rodrigues and Theunis Goosen (Pfizer Inc.) for helpful discussions, and Ms. Karen Atkinson (Pfizer Inc.) for assistance with manuscript editing.

Authorship Contributions

Participated in research design: Li, Niosi, Tess, Lin, El-Kattan, Maurer, Tremaine, and Di.

Conducted experiments: Niosi, Johnson, Kimoto, Yang, Riccardi, Ryn.

Contributed new reagents or analytic tools: Li.

Performed data analysis: Li, Niosi, Johnson, Kimoto, Tess, Tremaine, and Di

Wrote or contributed to the writing of the manuscript: Li, Johnson, and Di
References


DMD # 78790


Figure Captions

Figure 1. Schematic diagram of a PBPK model for bosentan. Only two liver segments are presented in this scheme, but there are five segments in the model. Non-liver tissue type II represents tissues whose venous blood enters portal vein, while type I represents the rest non-liver tissues.

Figure 2. Observed (circles) and simulated (solid lines) total systemic plasma concentrations of bosentan following intravenous dosing.

Figure 3. Observed (circles) and simulated (solid lines) total systemic plasma concentrations of bosentan following oral dosing. Subplots (A) to (F) show the multiple oral dosing with different amounts. Subplots (G) and (H) show the single oral dosing with high fat meal.

Figure 4. Observed (circles) and simulated (solid lines) total systemic plasma concentrations of tadalafil on day 1 (A and B), day 10 (C and D), S-warfarin (E and F), and R-warfarin (G and H). Subplots (A), (C), (E), and (G) represent pharmacokinetics in the absence of bosentan, while subplots (B), (D), (F), and (H) represent pharmacokinetics in the presence of bosentan.

Figure 5. Simulated total systemic and liver tissue concentrations (A, D, and G), ratios between unbound liver tissue and unbound systemic plasma concentrations (B, E, and H), and induction effect of bosentan (C, F, and I). In subplots (A, D, and G), red and blue curves represent systemic and liver concentrations. In subplots (C, F, and I), red and blue curves represent induction effects in enterocytes and liver. The solid lines and shaded areas represent median and 95% intervals of the simulations.

Figure 6. Simulated induction effect based on clinical data (green) and in vitro hepatocyte data (red, black, and blue). Red, blue, and black represent simulations based on hepatocyte lots HC7-4, HH1025, and FOS. The solid lines and shaded areas represent median and 95% intervals of the simulations.

Figure 7. (A) simulated inhibition of BSEP (black), MRP3 (green), and MRP4 (magenta) based on bosentan unbound liver tissue concentration, and (B) simulated inhibition of NTCP (cyan) based on bosentan unbound liver plasma concentration. The solid lines and shaded areas represent median and 95% intervals of the simulations.
Table 1. Bosentan clinical data included in the PBPK modeling exercise.

<table>
<thead>
<tr>
<th>Dosed compound(s)</th>
<th>Dosing route</th>
<th>Dosing amount</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bosentan</td>
<td>Intravenous infusion (5 min)</td>
<td>10, 50, 250, 500, 750 mg</td>
<td>(Weber et al., 1996)</td>
</tr>
<tr>
<td>Bosentan</td>
<td>Intravenous infusion (15 min)</td>
<td>250 mg</td>
<td>(Weber et al., 1999b)</td>
</tr>
<tr>
<td>Bosentan</td>
<td>Tablet after high fat meal</td>
<td>500 mg</td>
<td>(NDA-21-290, 2001)</td>
</tr>
<tr>
<td>Bosentan</td>
<td>Tablet after high fat meal</td>
<td>125 mg</td>
<td>(Dingemanse et al., 2002)</td>
</tr>
<tr>
<td>Bosentan</td>
<td>Tablet</td>
<td>500 mg</td>
<td>(Weber et al., 1999c)</td>
</tr>
<tr>
<td>Bosentan</td>
<td>Tablet</td>
<td>62.5 mg</td>
<td>(van Giersbergen et al., 2002b)</td>
</tr>
<tr>
<td>Bosentan (BID)</td>
<td>Tablet</td>
<td>125 mg bosentan</td>
<td>(Wrishko et al., 2008)</td>
</tr>
<tr>
<td>Tadalafil (QD)</td>
<td>Tablet</td>
<td>40 mg tadalafil</td>
<td></td>
</tr>
<tr>
<td>Bosentan (BID)</td>
<td>Tablet</td>
<td>500 mg bosentan</td>
<td></td>
</tr>
<tr>
<td>Warfarin (once on day 6)</td>
<td>Tablet</td>
<td>26 mg racemic mixture of warfarin</td>
<td>(Weber et al., 1999a)</td>
</tr>
</tbody>
</table>
Table 2. The list of parameters with fixed values in the described bosentan PBPK model.

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Unit</th>
<th>Value</th>
<th>Source</th>
<th>Parameter</th>
<th>Unit</th>
<th>Value</th>
<th>Source</th>
</tr>
</thead>
<tbody>
<tr>
<td>pKa</td>
<td></td>
<td>5.2 (acidic)</td>
<td>In-house</td>
<td>$k_{on}$</td>
<td>nmol$^{-1}$·hour$^{-1}$</td>
<td>3600</td>
<td>(Alberty and Hammes, 1958)</td>
</tr>
<tr>
<td>$\log D_{7.4}$</td>
<td></td>
<td>1.3</td>
<td>In-house</td>
<td>$k_{off, plasma}$</td>
<td>hour$^{-1}$</td>
<td>8.18×10$^7$</td>
<td>Supplemental Materials</td>
</tr>
<tr>
<td>MW</td>
<td>g·mol$^{-1}$</td>
<td>551.6</td>
<td>In-house</td>
<td>$k_{off,RBC}$</td>
<td>hour$^{-1}$</td>
<td>1.25×10$^7$</td>
<td>Supplemental Materials</td>
</tr>
<tr>
<td>$K_M, \text{liver, uptake}$</td>
<td>nM</td>
<td>4343</td>
<td>SCHH</td>
<td>$k_{off, liver, tissue}$</td>
<td>hour$^{-1}$</td>
<td>4.80×10$^7$</td>
<td>SCHH</td>
</tr>
<tr>
<td>$K_M, \text{liver, metabolism}$</td>
<td>nM</td>
<td>6.9×10$^4$</td>
<td>(Shen et al., 2009)</td>
<td>Binding site in plasma</td>
<td>nM</td>
<td>1.14×10$^6$</td>
<td>Supplemental Materials</td>
</tr>
<tr>
<td>$K_M, \text{enterocyte, metabolism}$</td>
<td>nM</td>
<td>6.9×10$^4$</td>
<td>(Shen et al., 2009)</td>
<td>Binding site in RBC</td>
<td>nM</td>
<td>4.11×10$^4$</td>
<td>Supplemental Materials</td>
</tr>
<tr>
<td>Ratio of $k_{\text{enterocyte, metabolism}}$ to $k_{\text{liver, metabolism}}$</td>
<td></td>
<td>0.0260</td>
<td>Supplemental Materials</td>
<td>Binding site liver tissue</td>
<td>nM</td>
<td>3.67×10$^4$</td>
<td>SCHH</td>
</tr>
<tr>
<td>$F_a, 62.5 \text{ mg tablet}$</td>
<td></td>
<td>0.973</td>
<td>Supplemental Materials</td>
<td>$CL_{\text{systemic, blood, pass}}$</td>
<td>L·hour$^{-1}$</td>
<td>1.12×10$^3$</td>
<td>Supplemental Materials</td>
</tr>
<tr>
<td>$F_a, 125 \text{ mg tablet}$</td>
<td></td>
<td>1</td>
<td>Supplemental Materials</td>
<td>$CL_{\text{liver, blood, pass}}$</td>
<td>L·hour$^{-1}$</td>
<td>72.5</td>
<td>Supplemental Materials</td>
</tr>
<tr>
<td>$F_a, 500 \text{ mg tablet}$</td>
<td></td>
<td>0.823</td>
<td>Supplemental Materials</td>
<td>$CL_{\text{villi, blood, pass}}$</td>
<td>L·hour$^{-1}$</td>
<td>2.43</td>
<td>Supplemental Materials</td>
</tr>
<tr>
<td>$F_a, 125 \text{ mg high fat}$</td>
<td></td>
<td>1</td>
<td>Supplemental Materials</td>
<td>CYP $k_{\text{enterocyte, degradation}}$</td>
<td>hour$^{-1}$</td>
<td>0.0300</td>
<td>(Yang et al., 2008)</td>
</tr>
<tr>
<td>$F_a, 500 \text{ mg high fat}$</td>
<td></td>
<td>1</td>
<td>Supplemental Materials</td>
<td>CYP $k_{\text{liver, degradation}}$</td>
<td>hour$^{-1}$</td>
<td>0.0250</td>
<td>(Quinney et al., 2010)</td>
</tr>
<tr>
<td>Human HCT</td>
<td></td>
<td>0.519</td>
<td>In-house</td>
<td>Induction $EC_{50}$</td>
<td>nM</td>
<td>1000</td>
<td>Hepatocyte induction assay</td>
</tr>
<tr>
<td>$IC_{50, NTCP}$</td>
<td>nM</td>
<td>2.4×10$^4$</td>
<td>(Leslie et al., 2007)</td>
<td>$IC_{50, MRP3}$</td>
<td>nM</td>
<td>4.2×10$^4$</td>
<td>(Morgan et al., 2013)</td>
</tr>
<tr>
<td>$IC_{50, BSEP}$</td>
<td>nM</td>
<td>2.3×10$^4$</td>
<td>(Morgan et al., 2013)</td>
<td>$IC_{50, MRP4}$</td>
<td>nM</td>
<td>2.2×10$^4$</td>
<td>(Morgan et al., 2013)</td>
</tr>
</tbody>
</table>
Table 3. Median values and 95% confidence intervals of optimized parameters in the bosentan PBPK model. Values and confidence intervals are estimated by fitting clinical data.

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Unit</th>
<th>Median</th>
<th>Confidence intervals</th>
</tr>
</thead>
<tbody>
<tr>
<td>ET $k_{off}$</td>
<td>hour$^{-1}$</td>
<td>$1.61 \times 10^4$</td>
<td>$7200, 3.4 \times 10^4$</td>
</tr>
<tr>
<td>ET total concentration</td>
<td>nM</td>
<td>2750</td>
<td>1400, 4900</td>
</tr>
<tr>
<td>$CL_{liver,pass}$</td>
<td>L⋅hour$^{-1}$</td>
<td>23.9</td>
<td>13, 44</td>
</tr>
<tr>
<td>$k_{liver,uptake}$</td>
<td>nmol⋅hour$^{-1}$</td>
<td>$4.78 \times 10^6$</td>
<td>$3.8 \times 10^6, 6.5 \times 10^6$</td>
</tr>
<tr>
<td>$k_{liver,metabolism}$</td>
<td>nmol⋅hour$^{-1}$</td>
<td>$1.00 \times 10^6$</td>
<td>$8.0 \times 10^5, 1.3 \times 10^6$</td>
</tr>
<tr>
<td>$k_{liver,efflux}$</td>
<td>nmol⋅hour$^{-1}$</td>
<td>$6.00 \times 10^4$</td>
<td></td>
</tr>
<tr>
<td>$K_{m,liver,efflux}$</td>
<td>nM</td>
<td>$1.48 \times 10^6$</td>
<td></td>
</tr>
<tr>
<td>$k_a$</td>
<td>hour$^{-1}$</td>
<td>0.932</td>
<td>0.81, 1.3</td>
</tr>
<tr>
<td>$k_a$ (meal)</td>
<td>hour$^{-1}$</td>
<td>0.759</td>
<td>0.64, 1.1</td>
</tr>
<tr>
<td>$f_{u,enterocyte}$</td>
<td></td>
<td>0.964</td>
<td>0.50, 1.0</td>
</tr>
<tr>
<td>$CL_{enterocyte,pass}$</td>
<td>L⋅hour$^{-1}$</td>
<td>$2.31 \times 10^{-5}$</td>
<td>$&lt; 1.1 \times 10^{-4}$</td>
</tr>
<tr>
<td>$CL_{enterocyte,efflux}$</td>
<td>L⋅hour$^{-1}$</td>
<td>$6.80 \times 10^{-5}$</td>
<td>$&lt; 1.1 \times 10^{-4}$</td>
</tr>
<tr>
<td>Clinical induction $E_{max}$</td>
<td></td>
<td>1.36</td>
<td>1.0, 1.7</td>
</tr>
<tr>
<td>Tadalafil $F_a F_g$ with bosentan</td>
<td></td>
<td>0.868</td>
<td>0.70, 1.0</td>
</tr>
<tr>
<td>S warfarin $F_a F_g$ with bosentan</td>
<td></td>
<td>1.10</td>
<td>0.99, 1.2</td>
</tr>
<tr>
<td>R warfarin $F_a F_g$ with bosentan</td>
<td></td>
<td>1.00</td>
<td>0.83, 1.3</td>
</tr>
</tbody>
</table>

* Median and confidence interval are not provided for the parameters with high uncertainty (i.e., the range of approximated confidence interval is greater than 20 magnitude). The globally optimized values (and upper bound if possible) are provided instead.
Table 4. Median values and 95% confidence intervals of optimized in vitro parameters ($E_{\text{max}}$ and $EC_{50}$) describing CYP induction due to bosentan.

<table>
<thead>
<tr>
<th>Assay</th>
<th>Hepatocyte lot*</th>
<th>$E_{\text{max}}$</th>
<th>$EC_{50}$ (nM)</th>
</tr>
</thead>
<tbody>
<tr>
<td>CYP2B6 activity</td>
<td>HC7-4</td>
<td>9.62 (8.4 and 11)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>HH1025</td>
<td>1.40 (1.1 and 1.7)</td>
<td>1440 (1100 and 1900)</td>
</tr>
<tr>
<td></td>
<td>FOS</td>
<td>9.13 (7.9 and 11)</td>
<td></td>
</tr>
<tr>
<td>CYP3A4 activity</td>
<td>HC7-4</td>
<td>11.0 (9.5 and 13)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>HH1025</td>
<td>1.62 (1.3 and 2.0)</td>
<td>433 (320 and 590)</td>
</tr>
<tr>
<td></td>
<td>FOS</td>
<td>8.26 (7.2 and 9.5)</td>
<td></td>
</tr>
<tr>
<td>CYP2B6 mRNA</td>
<td>HC7-4</td>
<td>11.1 (9.0 and 14)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>HH1025</td>
<td>11.2 (9.0 and 14)</td>
<td>958 (600 and 1500)</td>
</tr>
<tr>
<td></td>
<td>FOS</td>
<td>3.89 (3.0 and 5.0)</td>
<td></td>
</tr>
<tr>
<td>CYP3A4 mRNA</td>
<td>HC7-4</td>
<td>127 (110 and 150)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>HH1025</td>
<td>72.9 (60 and 89)</td>
<td>1118 (860 and 1500)</td>
</tr>
<tr>
<td></td>
<td>FOS</td>
<td>29.9 (25 and 36)</td>
<td></td>
</tr>
</tbody>
</table>

*HC7-4 and FOS are from male donors and HH1025 is from a female donor.
Figure 2.
Figure 3.
Figure 4.
Figure 5.
Figure 6.

(A) CYP2B6 activity

(B) CYP3A4 activity

(C) CYP2B6 mRNA

(D) CYP3A4 mRNA
Figure 7.

(A) bosentan oral dosing
500 mg BID day 10

(B) bosentan oral dosing
500 mg BID day 10